Researchers conducted a retrospective analysis to identify seasonal variations in outcomes for COPD exacerbation admissions and the effect on healthcare resource utilization.
Treatment with aclidinium bromide reduced the rate of exacerbations in patients with moderate to severe COPD and high cardiovascular risk.
One in 20 patients admitted to the hospital for an exacerbation of COPD was readmitted within 30 days.
In patients with COPD, revefenacin demonstrated a safety profile similar to that of formoterol alone when given either before or combined with formoterol through a standard jet nebulizer.
Depression is linked to increased clinical burden in patients with COPD.
Patients with COPD who have suboptimal peak inspiratory flow rate tend to have longer disease duration, be more symptomatic, have more severe airflow obstruction, and lower lung function, weight, and BMI.